These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 29247557)

  • 1. Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.
    Shen YQ; Guerra-Librero A; Fernandez-Gil BI; Florido J; García-López S; Martinez-Ruiz L; Mendivil-Perez M; Soto-Mercado V; Acuña-Castroviejo D; Ortega-Arellano H; Carriel V; Diaz-Casado ME; Reiter RJ; Rusanova I; Nieto A; López LC; Escames G
    J Pineal Res; 2018 Apr; 64(3):. PubMed ID: 29247557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
    Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
    Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer.
    Amornphimoltham P; Patel V; Leelahavanichkul K; Abraham RT; Gutkind JS
    Cancer Res; 2008 Feb; 68(4):1144-53. PubMed ID: 18281490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin inhibits carcinogen and nicotine-induced Mammalian target of rapamycin pathway activation in head and neck squamous cell carcinoma.
    Clark CA; McEachern MD; Shah SH; Rong Y; Rong X; Smelley CL; Caldito GC; Abreo FW; Nathan CO
    Cancer Prev Res (Phila); 2010 Dec; 3(12):1586-95. PubMed ID: 20851953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD‑L1 promotes head and neck squamous cell carcinoma cell growth through mTOR signaling.
    Zheng A; Li F; Chen F; Zuo J; Wang L; Wang Y; Chen S; Xiao B; Tao Z
    Oncol Rep; 2019 May; 41(5):2833-2843. PubMed ID: 30864729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition.
    Coppock JD; Wieking BG; Molinolo AA; Gutkind JS; Miskimins WK; Lee JH
    Neoplasia; 2013 Jun; 15(6):620-30. PubMed ID: 23730210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells.
    Xie J; Li Q; Ding X; Gao Y
    Cell Physiol Biochem; 2018; 46(2):676-686. PubMed ID: 29621758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
    Herzog A; Bian Y; Vander Broek R; Hall B; Coupar J; Cheng H; Sowers AL; Cook JD; Mitchell JB; Chen Z; Kulkarni AB; Van Waes C
    Clin Cancer Res; 2013 Jul; 19(14):3808-19. PubMed ID: 23640975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OP16, a novel ent-kaurene diterpenoid, potentiates the antitumor effect of rapamycin by inhibiting rapamycin-induced feedback activation of Akt signaling in esophageal squamous cell carcinoma.
    Peng KZ; Ke Y; Zhao Q; Tian F; Liu HM; Hou G; Lu Z
    Biochem Pharmacol; 2017 Sep; 140():16-27. PubMed ID: 28539264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines.
    Aissat N; Le Tourneau C; Ghoul A; Serova M; Bieche I; Lokiec F; Raymond E; Faivre S
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):305-13. PubMed ID: 17912526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
    Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
    Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells.
    Fang L; Wang H; Zhou L; Yu D
    Toxicol Appl Pharmacol; 2011 Feb; 251(1):8-15. PubMed ID: 21092744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.
    Coppock JD; Vermeer PD; Vermeer DW; Lee KM; Miskimins WK; Spanos WC; Lee JH
    Oncotarget; 2016 Apr; 7(17):24228-41. PubMed ID: 27015118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer.
    Bozec A; Ebran N; Radosevic-Robin N; Sudaka A; Monteverde M; Toussan N; Etienne-Grimaldi MC; Nigro CL; Merlano M; Penault-Llorca F; Milano G
    Laryngoscope; 2016 Apr; 126(4):E156-63. PubMed ID: 26597440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR kinase inhibitor pp242 causes mitophagy terminated by apoptotic cell death in E1A-Ras transformed cells.
    Gordeev SA; Bykova TV; Zubova SG; Bystrova OA; Martynova MG; Pospelov VA; Pospelova TV
    Oncotarget; 2015 Dec; 6(42):44905-26. PubMed ID: 26636543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
    Cirstea D; Hideshima T; Rodig S; Santo L; Pozzi S; Vallet S; Ikeda H; Perrone G; Gorgun G; Patel K; Desai N; Sportelli P; Kapoor S; Vali S; Mukherjee S; Munshi NC; Anderson KC; Raje N
    Mol Cancer Ther; 2010 Apr; 9(4):963-75. PubMed ID: 20371718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial.
    Day TA; Shirai K; O'Brien PE; Matheus MG; Godwin K; Sood AJ; Kompelli A; Vick JA; Martin D; Vitale-Cross L; Callejas-Varela JL; Wang Z; Wu X; Harismendy O; Molinolo AA; Lippman SM; Van Waes C; Szabo E; Gutkind JS
    Clin Cancer Res; 2019 Feb; 25(4):1156-1164. PubMed ID: 30420444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.
    Sun ZJ; Zhang L; Hall B; Bian Y; Gutkind JS; Kulkarni AB
    Clin Cancer Res; 2012 Oct; 18(19):5304-13. PubMed ID: 22859719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma.
    Chou MH; Chuang HC; Lin YT; Tsai MH; Kao YH; Lin IC; Huang TL; Fang FM; Chien CY
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma.
    Zhang L; Zhang W; Wang YF; Liu B; Zhang WF; Zhao YF; Kulkarni AB; Sun ZJ
    Cell Death Dis; 2015 May; 6(5):e1771. PubMed ID: 26018732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.